[{"orgOrder":0,"company":"Rejuvenate Biomed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"BELGIUM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Galantamine Hydrobromide","moa":"||Ach receptor","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Rejuvenate Biomed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rejuvenate Biomed \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rejuvenate Biomed \/ Inapplicable"},{"orgOrder":0,"company":"Canadian Cancer Society","sponsor":"Canadian Institutes Of Health Research","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Metformin","moa":"NADH dehydrogenase","graph1":"Neurology","graph2":"Phase III","graph3":"Canadian Cancer Society","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Canadian Cancer Society \/ Canadian Institutes Of Health Research","highestDevelopmentStatusID":"10","companyTruncated":"Canadian Cancer Society \/ Canadian Institutes Of Health Research"},{"orgOrder":0,"company":"Hua Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dorzagliatin","moa":"||Glucokinase","graph1":"Endocrinology","graph2":"Phase III","graph3":"Hua Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hua Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hua Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Chiglitazar Sodium","moa":"||PPAR","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shenzhen Chipscreen Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vildagliptin","moa":"||DPP-4","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Tiefenbacher Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tiefenbacher Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Tiefenbacher Group \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"HPAPI","year":"2023","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"||SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Remogliflozin Etabonate","moa":"||SGLT","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Metformin","moa":"NADH dehydrogenase","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"Indoco Remedies Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"HPAPI","year":"2024","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"||SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Indoco Remedies Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indoco Remedies Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Indoco Remedies Limited \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sitagliptin Phosphate","moa":"||DPP-4","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"||SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Saxagliptin","moa":"||DPP-4","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Akums Drugs & Pharmaceuticals Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sitagliptin Phosphate","moa":"||DPP-4","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Akums Drugs & Pharmaceuticals Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akums Drugs & Pharmaceuticals Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akums Drugs & Pharmaceuticals Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Mascot Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Glimepiride","moa":"||SUR 1\/Kir6.2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Mascot Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet, Bilayer","sponsorNew":"Mascot Health \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mascot Health \/ Inapplicable"},{"orgOrder":0,"company":"Macleods Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Glimepiride","moa":"||SUR 1\/Kir6.2","graph1":"Endocrinology","graph2":"Phase II","graph3":"Macleods Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Macleods Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Macleods Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Towa Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Vildagliptin","moa":"||DPP-4","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Towa Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Towa Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Towa Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Center Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"TAIWAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CS02","moa":"||HbA1c","graph1":"Endocrinology","graph2":"Phase II","graph3":"Center Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Center Laboratories \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Center Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Termination","leadProduct":"Dapagliflozin Propanediol Monohydrate","moa":"||SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Abbott Laboratories \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Abbott Laboratories \/ AstraZeneca"},{"orgOrder":0,"company":"Anji Pharmaceutical","sponsor":"Population Health","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Metformin","moa":"NADH dehydrogenase","graph1":"Endocrinology","graph2":"Phase III","graph3":"Anji Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Anji Pharmaceutical \/ Population Health","highestDevelopmentStatusID":"10","companyTruncated":"Anji Pharmaceutical \/ Population Health"},{"orgOrder":0,"company":"Anji Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Metformin","moa":"NADH dehydrogenase","graph1":"Endocrinology","graph2":"Phase III","graph3":"Anji Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Anji Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Anji Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Anji Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Metformin","moa":"NADH dehydrogenase","graph1":"Endocrinology","graph2":"Phase III","graph3":"Anji Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Anji Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Anji Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Metformin","moa":"NADH dehydrogenase","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"George Medicines","sponsor":"CUREator","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Metformin","moa":"||NADH dehydrogenase","graph1":"Endocrinology","graph2":"Phase II","graph3":"George Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"George Medicines \/ CUREator","highestDevelopmentStatusID":"8","companyTruncated":"George Medicines \/ CUREator"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"||SGLT2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"}]
Find Clinical Drug Pipeline Developments & Deals for Glucophage
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
Towa Pharma is dedicated to researching, developing, producing, and promoting generic drugs.
